



江苏美克医学技术有限公司
Jiangsu Medomics Medical Technology Co.,Ltd

DECLARATION

Medomics hereby declares,

Medomics SARS-CoV-2 Antigen Test Kit (LFIA) is suitable for in vitro qualitative detection of SARS-CoV-2 Nucleocapsid proteins in samples.

The binding site is 79-88, 113-165.

The mutation site of Nucleocapsid protein in South African variant(B.1.1.529) was 13,33,203,204.

The variants Nucleocapsid proteins can be effectively detected by the Kit.
Therefore, this variant does not cause false negative results.

Thank you for your support.

11/26/2021
江苏美克医学技术有限公司
Jiangsu Medomics Medical Technology Co.,Ltd.
Stamp and Signature

A handwritten signature in blue ink, appearing to read "Kangjun Sun".

Add: F3, BuildingD, No.3-1XinjinhuRoad, Jiangbei New Area, Nanjing, Jiangsu

Tel: +86 (025) 58601060